Skip to main content
NVO
NYSE Life Sciences

Novo Nordisk's FREHEMGO Secures CHMP Backing for EU Approval in Haemophilia A

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$42.97
Mkt Cap
$184.764B
52W Low
$35.12
52W High
$64.16
52W Position info
22% above low
Off High info
33% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

NVO sits 22% above its 52-week low of $35.12.

Summary

CHMP recommended EU approval of FREHEMGO (denecimig) for haemophilia A, with launch expected in Q4 2026. The drug offers flexible monthly, biweekly and weekly dosing in a pre-filled pen.


Key Events · Product Development and Regulatory · NVO

  • CHMP Recommends EU Approval

    CHMP adopted a positive opinion recommending marketing authorisation for FREHEMGO (denecimig) to treat haemophilia A, with or without inhibitors, in adults and children.

  • First-in-Class Dosing Flexibility

    FREHEMGO is the first FVIIIa mimetic to offer once-monthly, once-every-two-weeks and once-weekly prophylaxis in a single-use pre-filled pen.

  • EU Launch Timeline

    Novo expects to launch FREHEMGO in the first European countries in Q4 2026 and broadly across the EU starting early 2027.

  • FRONTIER Efficacy and Safety

    Across the FRONTIER programme, denecimig showed mean annualised bleeding rates generally below 1, with a substantial proportion of participants experiencing zero treated bleeds; FRONTIER 5 found no new safety signals when switching directly from emicizumab.


Analysis · NVO · Life Sciences

A positive CHMP opinion clears the path for EU marketing authorisation of FREHEMGO (denecimig), Novo's next-generation FVIIIa mimetic for haemophilia A. The drug is the first in its class to offer once-monthly, once-every-two-weeks and once-weekly prophylaxis in a pre-filled pen, a dosing flexibility that could meaningfully differentiate it from Roche's emicizumab (Hemlibra). Launch in the first European countries is expected in Q4 2026, with a broader EU rollout starting early 2027. The FRONTIER programme showed annualised bleeding rates generally below 1 and a substantial proportion of patients with zero treated bleeds, with no new safety signals when switching directly from emicizumab. This is a meaningful commercial catalyst for Novo's rare disease franchise, which has been overshadowed by the GLP-1 portfolio.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NVO was trading at $42.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $184.8B. The 52-week trading range was $35.12 to $64.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NVO - Latest Insights

NVO
Nov 04, 2026, 8:35 AM EST
Source: Benzinga
Importance Score:
8
Price at Filing: $42.91
Real-time Price: $37.82 info
Change: -$5.09 (-12%) info
Market Cap: $171.535B info
NVO
Nov 04, 2026, 7:47 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $42.90
Real-time Price: $37.82 info
Change: -$5.08 (-12%) info
Market Cap: $171.535B info
NVO
Nov 04, 2026, 4:00 AM EST
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $41.96
Real-time Price: $37.82 info
Change: -$4.14 (-10%) info
Market Cap: $171.535B info
NVO
Oct 27, 2026, 3:10 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $39.16
Real-time Price: $37.82 info
Change: -$1.34 (-3%) info
Market Cap: $171.535B info
NVO
Oct 02, 2026, 5:53 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $36.88
Real-time Price: $37.82 info
Change: +$0.940 (+3%) info
Market Cap: $171.535B info